<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04546555</url>
  </required_header>
  <id_info>
    <org_study_id>00000988</org_study_id>
    <nct_id>NCT04546555</nct_id>
  </id_info>
  <brief_title>Physiologic Accelerated Pacing as a Treatment in Patients With Heart Failure With Preserved Ejection Fraction</brief_title>
  <acronym>PACE HFpEF</acronym>
  <official_title>Physiologic Accelerated Pacing as a Treatment in Patients With Heart Failure With Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daniel L Lustgarten</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Vermont</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part I: Week 0-12: Quantify the effects of lower heart rate (HR) elevation on symptoms and&#xD;
      function in patients with heart failure with preserved ejection fraction (HFpEF).&#xD;
&#xD;
      The investigators hypothesize that a personalized lower HR elevation employing physiological&#xD;
      conduction system pacing in patients with HFpEF will decrease left atrial and left&#xD;
      ventricular filling pressures. The investigators expect that this will result in a&#xD;
      symptomatic and functional improvements and reduce NTproBNP levels. Additionally, HR&#xD;
      elevation may have the potential to reduce the risk for heart failure hospitalization, atrial&#xD;
      fibrillation (AF), and cerebrovascular stroke as these outcomes are increased in patients&#xD;
      with a normal or preserved ejection fraction on HR lowering treatments.&#xD;
&#xD;
      After undergoing pacemaker implantation participants will be randomized to one out of three&#xD;
      treatment arms (a) Bachmann's bundle pacing, (b) Bachmann's bundle and His bundle pacing, (c)&#xD;
      no pacing with cross-over to alternative treatment arm at week 4 and 8, respectively. The&#xD;
      lower pacing rate in arms a and b will be programmed to the personalized lower heart rate for&#xD;
      24 hours a day (the patient's intrinsic heart rate can exceed the personalized lower rate&#xD;
      limit).&#xD;
&#xD;
      Part II: Week 13-20: Determine the effects of nocturnal heart rate elevation on symptoms and&#xD;
      function in patients with HFpEF.&#xD;
&#xD;
      The investigators hypothesize that a moderate HR elevation to 110bpm delivered for 10 hours&#xD;
      between 8PM to 6AM will provide additional hemodynamic benefits and will lead to beneficial&#xD;
      ventricular remodeling.&#xD;
&#xD;
      After week 12 the participant will undergo randomization to one of two treatment arms (a)&#xD;
      Bachmann's bundle and His bundle pacing, (b) Bachmann's bundle pacing, His bundle pacing and&#xD;
      nocturnal pacing. The participant will cross-over to the other treatment arm after 4 weeks&#xD;
      (study week 16).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">February 28, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in composite Minnesota-Living-with-Heart-Failure-Questionnaire score</measure>
    <time_frame>At 1 month, 2 months, 3 months, 4 months and 5 months</time_frame>
    <description>Total score can range from 0 to 105, with higher scores indicating more significant impairment in health-related quality of life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change in NTproBNP</measure>
    <time_frame>At 1 month, 2 months, 3 months, 4 months and 5 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in 6 minute walk test</measure>
    <time_frame>At 1 month, 2 months, 3 months, 4 months and 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incident AF</measure>
    <time_frame>At 1 month, 2 months, 3 months, 4 months and 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Burden of AF</measure>
    <time_frame>At 1 month, 2 months, 3 months, 4 months and 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic changes by Echo</measure>
    <time_frame>At 3 months and at 5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in left ventricular mass/volume ratio by cardiac MRI</measure>
    <time_frame>5 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Quantitative assessment of the risks of pacemaker implantation</measure>
    <time_frame>1 month</time_frame>
    <description>Incidence of pocket hematoma, pocket infection phrenic or diaphragmatic stimulation, lead endocarditis, lead dysfunction/dislocation, pneumothorax, hemopericardium, mortality</description>
  </other_outcome>
  <other_outcome>
    <measure>Doubling in baseline Troponin or NTproBNP</measure>
    <time_frame>At 1 month, 2 months, 3 months, 4 months and 5 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>&gt;= 25% increase in systolic blood pressure</measure>
    <time_frame>At 1 month, 2 months, 3 months, 4 months and 5 months</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Heart Failure, Diastolic</condition>
  <arm_group>
    <arm_group_label>No pacing</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bachmann's bundle pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bachmann's bundle and His bundle pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Bachmann's bundle, His bundle and nocturnal pacing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dual chamber pacemaker</intervention_name>
    <description>Dual chamber pacemaker implantation with Bachmann's bundle lead and His bundle lead placement.</description>
    <arm_group_label>Bachmann's bundle and His bundle pacing</arm_group_label>
    <arm_group_label>Bachmann's bundle pacing</arm_group_label>
    <arm_group_label>Bachmann's bundle, His bundle and nocturnal pacing</arm_group_label>
    <arm_group_label>No pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Accelerated Physiologic Pacing</intervention_name>
    <description>The lower rate limit will be programmed to an individualized heart rate.</description>
    <arm_group_label>Bachmann's bundle and His bundle pacing</arm_group_label>
    <arm_group_label>Bachmann's bundle pacing</arm_group_label>
    <arm_group_label>Bachmann's bundle, His bundle and nocturnal pacing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nocturnal Pacing</intervention_name>
    <description>In addition to adjustment of the lower rate limit to an individualized heart rate, nocturnal pacing a moderate HR elevation of 110bpm will be implemented between 8pm and 6am.</description>
    <arm_group_label>Bachmann's bundle, His bundle and nocturnal pacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Left ventricular ejection fraction â‰¥ 50% (and diastolic volume &lt; 80ml/m2)&#xD;
&#xD;
          -  Controlled blood pressure for at least 30 days (BP &lt; 130/80mmHg)&#xD;
&#xD;
          -  Heart failure hospitalization within the past 12 months OR Echocardiogram within the&#xD;
             past 24 months that reported left ventricular hypertrophy AND an NTproBNP &gt;400 with at&#xD;
             least one symptom of heart failure (dyspnea on exertion, orthopnea or paroxysmal&#xD;
             nocturnal dyspnea) and at least one sign of heart failure in the past 12 months&#xD;
             (pulmonary edema or pleural effusion on chest x-ray, lower extremity edema, jugular&#xD;
             venous distention, rales).&#xD;
&#xD;
          -  Study candidates are expected to remain available for follow-up visits.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has an implanted cardiac pacemaker or defibrillator&#xD;
&#xD;
          -  Life expectancy is less than 12 months&#xD;
&#xD;
          -  Subject is unable or unwilling to perform the 6 Minute Walk Test and MLHFQ at all&#xD;
             scheduled follow up visits&#xD;
&#xD;
          -  Subject has any of the following: uncontrolled hypertension, more than moderate&#xD;
             valvular disease, chronic hypoxic respiratory failure requiring supplemental oxygen,&#xD;
             long-standing persistent atrial fibrillation&#xD;
&#xD;
          -  Baseline ECG with non-LBBB morphology AND QRS &gt;150ms&#xD;
&#xD;
          -  Subject is currently enrolled or planning to enroll in a potentially confounding trial&#xD;
             during the course of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicole Habel, MD</last_name>
    <phone>8028472270</phone>
    <email>nicole.habel@uvmhealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Vermont Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Habel, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 14, 2020</study_first_posted>
  <last_update_submitted>February 24, 2021</last_update_submitted>
  <last_update_submitted_qc>February 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Vermont</investigator_affiliation>
    <investigator_full_name>Daniel L Lustgarten</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Physiologic Pacing</keyword>
  <keyword>His Bundle Pacing</keyword>
  <keyword>Bachmann's Bundle Pacing</keyword>
  <keyword>HFpEF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Heart Failure, Diastolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

